Renal Denervation for Resistant Hypertension Not Dead Yet∗ by Reddy, Vivek Y. & Olin, Jeffrey W.
J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y V O L . 6 4 , N O . 1 1 , 2 0 1 4
ª 2 0 1 4 B Y T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 0 7 3 5 - 1 0 9 7 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j a c c . 2 0 1 4 . 0 7 . 9 4 7EDITORIAL COMMENTRenal Denervation for
Resistant Hypertension
Not Dead Yet*Vivek Y. Reddy, MD, Jeffrey W. Olin, DOT here are few areas in medicine that havegained as much prominence as quickly, orhave been as widely dismissed as quickly,
as catheter-based renal sympathetic denervation
(RDN) for the treatment of resistant hypertension.
Hypertension is a global public health concern
affecting 20% to 30% of the world’s population
despite advances in medical treatment and patient
education (1). Of these cases, it is estimated that
10% have resistant hypertension—deﬁned as a sys-
tolic blood pressure (SBP) of at least 140 mm Hg
despite adherence to at least 3 antihypertensive med-
ications, including a diuretic, at maximally tolerated
doses. Furthermore, it has been shown that more
than 50% of patients with resistant hypertension
are nonadherent to their medications (2). Given
the aging population and the concurrent obesity
epidemic, the prevalence of hypertension is only
expected to increase worldwide.
The concept of interfering with the sympathetic
nervous system to treat essential hypertension has
been around for more than 75 years (3–5). In addition
to a nonrandomized surgical series in the 1960s (4),
RDN emerged as a possible treatment strategy based
on: 1) pre-clinical studies demonstrating a patholog-
ical role for increased sympathetic tone in animal
models of hypertension (6); 2) early clinical studies
demonstrating elevated sympathetic tone in patients
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blood pressure (BP) in patients with resistant hyper-
tension in both a ﬁrst-in-man nonrandomized clinical
series, SYMPLICITY HTN-1 (8), and an open-label ran-
domized controlled clinical trial, SYMPLICITY HTN-2
(9). Although neither of these studies was placebo-
controlled, the magnitude of effect on BP in these pa-
tients with resistant hypertension was dramatic: a
decrease of systolic/diastolic ofﬁce BP of 32/12 mm Hg
with no signiﬁcant change in the control group (9).
Additional follow-up demonstrated sustained re-
ductions in BP of a similar magnitude over 3 years for
both SYMPLICITYHTN-1 and -2 (10,11). Hering et al. (12)
showed that RDN was not only effective in reducing
BP, but that there was sustained reduction in muscle
sympathetic nerve activity for 1 year after RDN.
However, enthusiasm surrounding RDN for resis-
tant hypertension virtually evaporated over night
with the publication of the single-blind, randomized,
sham-controlled trial, SYMPLICITY HTN-3 (13). Unlike
prior studies, patients in SYMPLICITY HTN-3 under-
went screening renal angiography prior to randomi-
zation, so they were blinded to the treatment
assignment. Although there were no signiﬁcant safety
concerns with RDN, there was also no signiﬁcant
change in the primary efﬁcacy endpoint of ofﬁce
systolic BP at 6 months: a mean decrease of 14  24
mm Hg in the RDN and 12  26 mm Hg in the placebo
group, for a difference of 2.4 mm Hg (p ¼ 0.26 for a
superiority margin of 5 mm Hg) (13). Not surprisingly,
there has been much controversy over these results
and a number of theories on why SYMPLICITY HTN-3
had negative ﬁndings. Yet, despite the negative re-
sults in SYMPLICITY HTN-3, there continues to be
much interest in renal denervation. A PubMed search
revealed that approximately 260 papers on RDN
have been published in the ﬁrst 6 months of 2014 for
resistant hypertension, diabetes, proteinuria, heart
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1089failure, reduction in left ventricular mass, atrial
ﬁbrillation, and a host of other indications.
In this editorial, we review some of these theories,
particularly in the context of 2 papers published in












FIGURE 1 24-h Ambulatory Systolic Blood Pressure Changes in the SYMPLICITY Trials
Shown are the changes in the mean 24-h ambulatory systolic blood pressures between
baseline and 6 months in the various Symplicity trials. Unlike in SYMPLICITY HTN-3, 24-h
ambulatory blood pressure monitor recordings were not performed in all patients in the
ﬁrst 2 trials. The data shown are from those subset of patients in SYMPLICITY HTN-1
(n ¼ 12) and -2 (n ¼ 20/renal sympathetic denervation [RSDN], n ¼ 25/control) for whom
the data were available. Since SYMPLICITY HTN-1 did not have a control group, no data are
shown for that ﬁeld.
SEE PAGES 1071 AND 1079There have been several clinical trial design con-
cerns raised about SYMPLICITY HTN-3. First is the
concern that the BP may not have been stabilized
appropriately prior to randomization. Per protocol,
medication changes were not allowed in the 2 weeks
before randomization, even though many studies
have indicated that up to 8 weeks are required to
reach a steady state after introducing new drugs or a
change in dosage. However, only 31 patients (5.8%)
had medication changes during this period, with no
signiﬁcant between-group difference in ofﬁce BP at
screening visits (14). There is also the important effect
of regression to the mean, which can occur whenever
inclusion into a trial is based on exceeding a threshold
of a clinical marker that naturally ﬂuctuates with
time, such as BP. That is, a patient has a better chance
of meeting the inclusion criteria on the day when
their ﬂuctuating BP is above their own average. But
during follow-up, the average BP will tend to return to
that individual’s true mean pressure, even in absence
of an intervention. However, this regression to the
mean phenomenon is likely to be minimized when
one employs a 24-h ambulatory blood pressure
monitor (ABPM), which averages multiple values ob-
tained over the course of 24 h. In this context, the
publication by Bakris et al. (14) examined the ABPM
changes between groups in SYMPLICITY HTN-3, a
powered secondary efﬁcacy endpoint.
Unlike thew10-mmHgdrop in themean ambulatory
systolic BP seen in SYMPLICITYHTN-1 and -2 (Figure 1),
there was only a 6.8  15.0-mm Hg drop in the RDN
group in SYMPLICITY HTN-3, and this was not statis-
tically different than the 4.8  17.0-mm Hg drop in the
sham group (p ¼ 0.98, for a superiority margin of
2 mm Hg). The availability of 24-h BP values also
allowed the investigators to examine the difference in
BP between daytime and nighttime. Normally, there is
a decrease in nocturnal BP, but this normal diurnal BP
variation may be absent or even paradoxical (termed a
“nondipper” response) in certain hypertensive pa-
tients, and this is associated with worsened end-organ
damage and clinical outcomes (16). To this point,
Bakris et al. (14) now report that in SYMPLICITYHTN-3,
there were no signiﬁcant differences between groups
in the daytime systolic ABPM (1.1 mm Hg difference,
p ¼ 0.52), nocturnal systolic AMBP (3.3 change, p ¼0.06), or the percent of nondippers converting to dip-
pers (21.2% and 15.0% in the denervation and sham
groups, respectively, p ¼ 0.30) (14). Although the
trend for improved nocturnal ambulatory BP control
following RDN is interesting, the overall negative re-
sults are directionally consistent with the initially-
reported negative conclusion based on the ofﬁce BP.
The ABPM analysis was also important in the
subgroup interpretation of SYMPLICITY HTN-3. Un-
like prior RDN studies, which largely included only
Caucasian patients, SYMPLICITY HTN-3 was the ﬁrst
to include a signiﬁcant percentage (w26%) of black
hypertensive patients. The initial subgroup analysis
of ofﬁce BP in SYMPLICITY HTN-3 suggested that
RDN was only ineffective in black individuals and
would have been effective if these patients had been
excluded (13). However, the ABPM data failed to
demonstrate any signiﬁcant interaction with race and
BP outcome: there was no signiﬁcant difference in
24-h systolic BP change between black and nonblack
individuals (p value for interaction ¼ 0.643) (14).
Finally, the ABPM analysis is important in eluci-
dating the effect of baseline BP. That is, a high base-
line BP has been thought to be a clinical predictor of
response to RDN—with a greater response observed in
patients with a higher initial BP. Indeed, in the ﬁrst
analysis of the Global Symplicity Registry, which
included w1,000 patients treated worldwide, the
RDN-based 6-month reduction in the ofﬁce systolic
BP was 20  22 mm Hg in those patients with a
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with a 12  25 mm Hg reduction in the full Global
Symplicity Registry cohort (17). However, when the
SYMPLICITY HTN-3 cohort was divided into tertiles
based on the baseline 24-h ABPM, there was no sig-
niﬁcant difference in the systolic BP between the RDN
and sham groups for any of the 3 tertiles (mean
reduction of 1.6, 3.4, and 1.2 mm Hg for each tertile;
p ¼ NS for each) (18). However, it should be noted that
there was a decrease in the SBP of 11.0 mm Hg at 6
months in the sham group. The concept of this study
was to enter patients whose BP could not be
controlled on a good triple-drug regimen. How, then,
was there such a dramatic BP response in the sham
group, when these patients were entered because
their BP could not be controlled?
Bakris et al. (14) outline several possible reasons
why this trial did not meet its primary or secondary
endpoints and why BP reduction was not as robust as
in previous trials. There did not appear to be a differ-
ence in response based on those operators who
performed<5 procedures and thosewho performed$5
procedures. There were 111 operators who performed
at least 1 procedure (31% performed only 1 procedure).
Overall, there were 183 patients treated by physicians
who performed$5 procedures and 181 patients treated
by physicians who performed <5 procedures. There
was no difference in the 6-month change in ofﬁce,
ambulatory, or home BPs between these 2 groups. In
SYMPLICITY HTN-1 and -2, there were relatively few
operators, whereas in SYMPLICITY HTN-3, there were
many. Did some centers have a better response to
denervation than other centers?
Among the possible explanations for lack of efﬁ-
cacy (lack of validation of medication adherence,
Hawthorne effect, poor patient selection, and sym-
pathetic nervous system was not mediating the hy-
pertension), it is the inability to determine that
effective renal denervation has occurred that is most
disconcerting. To assess the efﬁcacy of renal dener-
vation, Tzafriri et al. (15) evaluated nerve and ganglia
distribution as it relates to effective denervation.
These investigators conducted a porcine pre-clinical
study using a multielectrode radiofrequency abla-
tion catheter. Although this catheter was different
than that used in the Symplicity studies, it nonethe-
less delivered ablation energy in a focal manner. This
study demonstrated that the number and density of
the nerves and ganglion were the greatest at the
proximal portion of the renal artery; however, they
are farther from the lumen of the artery. In the more
distal portions of the renal artery, the nerves are less
abundant but are closer to the lumen, making abla-
tion easier and more effective. These investigatorshave shown that at the ostium, an ablation up to
5 mm will affect <38% of the nerves.
Furthermore, treatment efﬁcacy, as deﬁned by a
decrease in renal cortical norepinephrine (NEPI)
levels, was only observed in 1 of 8 treated vessels,
where ablation involved all 4 circumferential quad-
rants, reached a depth of 9.1 mm, and affected 50% of
nerves. There was a correlation between the kidney
NEPI and the percentage of effectively ablated
nerves. NEPI levels remained at baseline for treat-
ments that affected #20% of nerves in the treated
segment (15).
These ﬁndings have important implications when
planning future clinical trials and highlight the
potentially signiﬁcant inﬂuence of procedural tech-
nique and technology on RDN outcomes. Indeed,
there are 3 pieces of corroborating data that implicate
procedural technique as an important factor in BP
outcome. First, it is important to recognize that, un-
like many interventional procedures, RDN does not
have a validated physiological procedure endpoint.
Indeed, the only procedural endpoint variable re-
ported in SYMPLICITY HTN-3 was the number of
“notches” on the post-ablation angiogram, signifying
energy delivery sufﬁcient to cause spasm of the ar-
tery: the majority of patients exhibited 0 (41%), 1
(21%), or 2 (16%) notches only (19). This questionable
technical success of the procedure is not terribly
surprising given that in SYMPLICITY HTN-3: 1) there
was no roll-in phase to the trial to permit operators to
develop technical expertise; 2) a total of 364 pro-
cedures were performed by 111 operators, who on
average had only performed w3 procedures; and 3) a
recent subanalysis of SYMPLICITY HTN-3 demon-
strated that only 25% of patients received 4-quadrant
ablation in at least 1 renal artery (19). Second, the
SYMPLICITY HTN-3 subanalysis also demonstrated a
statistically signiﬁcant positive correlation between
the number of ablation lesions/patient and the BP
difference between RDN and sham; that is, more
ablation lesions correlated to improved BP response
(19). Finally, there was a recent case report of a pa-
tient who underwent an uncomplicated RDN proce-
dure and died 12 days later from an unrelated
dissection of the ascending aorta, thereby allowing
for autopsy examination (20). Interestingly, histopa-
thology of the adventitial nerves around the renal
arteries revealed that ablation-related damage did
not penetrate beyond 2 mm from the luminal sur-
face, with signiﬁcant tapering toward the adventitia
where the nerve bundles are located. At least in
this patient, the RDN procedure was minimally
effective in interrupting the perirenal sympathetic
ﬁbers. Additionally, there is an emerging body of
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operator-to-operator variability in the technical per-
formance of the procedure.
There are critical questions that need to be
answered to better delineate the role of RDN for pa-
tients with resistant hypertension:
1. Is there a particular population of patients who are
responders and others who are less likely to
respond? Direct measures of sympathetic over-
activity, such as renal NEPI spillover or muscle
sympathetic nerve activity, are impractical for
even clinical trial use, much less clinical use. But,
perhaps there are clinical factors identifying pa-
tients with high sympathetic activity such as
nonresponse to aldosterone antagonist use at
baseline—as suggested in the subanalyses of
SYMPLICITY HTN-3 (13,14). Or, perhaps, one may
employ pre-procedural testing such as cardiac bar-
oreﬂex sensitivity as assessed by phase-rectiﬁed
signal averaging to identify patients with resistant
hypertension most likely to respond to RDN (21).
2. How important is technique and experience when
performing RDN? It is important for the sponsors of
SYMPLICITY HTN-3 to evaluate and make public
any differences in response among differentcenters. Improved technical aspects of the proce-
dure and the ability to identify effective denerva-
tion at the time of the procedure are important
aspects that will help to improve outcomes.
3. Perhaps, radiofrequency RDN is not the most effec-
tive method to deliver a deeper and a more circum-
ferential spread to achieve better sympathetic nerve
destruction. There are many companies working on
different methods of RDN, such as ultrasound or
local pharmacologic injection of neurotoxic agents.
4. Does the information provided by Tzafriri et al. (15)
help to design a clinical trial that would provide
more effective denervation? Ultimately, it will only
be as a result of additional carefully-conducted
clinical trials that we can fully appreciate which
hypertensive patients, if any, will beneﬁt from
renal sympathetic denervation.
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